

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>ABG WTT-MedAvail Ltd</u> _____ (Last) (First) (Middle) UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL _____ (Street) HONG KONG K3 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MedAvail Holdings, Inc. [MDVL]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/16/2023	
4. If Amendment, Date of Original Filed (Month/Day/Year)		
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Warrant (Right to Buy)	\$0.3854	06/16/2023		J ⁽¹⁾		6,818,181		06/16/2023	06/16/2028	Common Stock	6,818,181	(1)	6,818,181	I	See footnote ⁽²⁾
Series A Warrant (Right to Buy)	\$0.3854	06/16/2023		J ⁽¹⁾		965,130		06/16/2023	06/16/2028	Common Stock	965,130	(1)	965,130	I	See footnote ⁽³⁾

1. Name and Address of Reporting Person*
ABG WTT-MedAvail Ltd

 (Last) (First) (Middle)
 UNIT 3002-3004, 30TH FLOOR
 GLOUCESTER TOWER, THE LANDMARK, CENTRAL

 (Street)
 HONG KONG K3

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.

 (Last) (First) (Middle)
 UNIT 3002-3004, 30TH FLOOR
 GLOUCESTER TOWER, THE LANDMARK, CENTRAL

 (Street)
 HONG KONG K3

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ABG-WTT Global Life Science Capital Partners GP, L.P.

 (Last) (First) (Middle)
 UNIT 3002-3004, 30TH FLOOR

GLOUCESTER TOWER, THE LANDMARK, CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ABG-WTT Global Life Science Capital Partners GP Ltd](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ABG Management Ltd.](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Yu Fan](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Ally Bridge MedAlpha Master Fund L.P.](#)

(Last) (First) (Middle)

430 PARK AVENUE, 12TH FLOOR,

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Ally Bridge Group \(NY\) LLC](#)

(Last) (First) (Middle)

430 PARK AVENUE, 12TH FLOOR,

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Explanation of Responses:

1. On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of \$0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023.

2. These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.

3. These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.

Remarks:

Ally Bridge Group-WTT Global Life Science Capital Partners, L.P., By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: /s/ Fan Yu, Director 06/21/2023

ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu, Director 06/21/2023

ABG-WTT Global Life Science Capital Partners GP Limited, By: /s/ Fan Yu, Director 06/21/2023

Ally Bridge MedAlpha Master Fund L.P., By: Ally Bridge MedAlpha General Partner L.P., its general partner, By: Ally Bridge MedAlpha GP, LLC, its general partner, By: /s/ Fan Yu, Manager 06/21/2023

Ally Bridge Group (NY) LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director 06/21/2023

ABG Management Ltd., By: /s/ Fan Yu, Director 06/21/2023

ABG WTT-MedAvail Limited, By: /s/ Charles Chon, Director 06/21/2023

/s/ Fan Yu 06/21/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.